COFUL REMEDY Taiwan Chingguan No.1(NRICM101) by Li Kang Biotechnical

COFUL REMEDY Taiwan Chingguan No.1(NRICM101) by Li Kang Biotechnical
Product Description

NRICM101 was developed by Taiwan's National Research Institute of Chinese Medicine in 2020 as a treatment for mild to moderate COVID-19. It combines traditional Chinese medicinal theory with modern clinical practice. This concentrated herbal granule formulation contains 10 herbs, produced under GMP-certified manufacturing, with patent and trademark protection.

Approved for Emergency Use Authorization (EUA) by Taiwan's Ministry of Health and Welfare on June 4, 2021, NRICM101 has since been exported to countries such as Singapore. In the EU, it can be registered as a health supplement or herbal granule.

Read more Show less

Taiwan Institute of Economic Research

  • Country/Region:
    Taiwan
  • On CPHI since:
    2025
  • Certificates:
    2
  • Employees:
    500 - 999
Company types
Academic/Research
Association/Government
Contract Service
Manufacturer/Innovator
OTC
Pharmaceutical company
Primary activities
API Producer
Contract Manufacturer
Natural Extracts
Nutraceuticals
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    Immune Health; Clinically Proven & Mechanism Highlights:

    •In clinical use at Tri-Service General Hospital and Taichung Veterans General Hospital, hospitalized patients who took NRICM101 tested negative for COVID-19 three times within an average of 9 days, with no notable adverse effects.

    •Real-World Studies (RWS) showed 0% progression to severe disease in patients treated with NRICM101, compared to a 9.3% progression rate in the control group.

    •Molecular pharmacology studies demonstrate multi-target antiviral action: blocking viral entry (ACE2-Spike), inhibiting 3CL protease, and reducing pro-inflammatory cytokines IL-6 and TNF-a, helping to mitigate lung injury.
  • Model
    concentrated herbal granule
  • Supplied from
    Taiwan
More specifications Fewer specifications
Sales Markets
Show more Show less

Taiwan Institute of Economic Research

  • Country/Region:
    Taiwan
  • On CPHI since:
    2025
  • Certificates:
    2
  • Employees:
    500 - 999
Company types
Academic/Research
Association/Government
Contract Service
Manufacturer/Innovator
OTC
Pharmaceutical company
Primary activities
API Producer
Contract Manufacturer
Natural Extracts
Nutraceuticals
View company profile

More Products from Taiwan Institute of Economic Research (2)

  • COVRelief (NRICM101) by Chuang Song Zong Pharmaceutical Co., LTD.

    Product COVRelief (NRICM101) by Chuang Song Zong Pharmaceutical Co., LTD.

    “COVRelief ” EUIPO Trade mark No. 018316519COVRelief (NRICM101) is a prescription traditional Chinese medicine (TCM)developed by the National Research Institute of Chinese Medicine (NRICM) MOHWin 2020 for the symptom relief of mild to moderate COVID-19 infection. Thecomponents of NRICM101 were designed bas...
  • Taiwan NRICM201 by Li Kang Biotechnical Co., Ltd.

    Product Taiwan NRICM201 by Li Kang Biotechnical Co., Ltd.

    Developed by integrating Traditional Chinese Medicine and modern neuroscience, NRICM201 is a multi-herbal formulation specifically designed to support cognitive health in older adults and individuals with mild cognitive concerns. The formula includes documented herbal extracts such as Gastrodia...

Taiwan Institute of Economic Research resources (2)

  • Taiwan Showcases Evidence-Based TCM at CPHI Frankfurt 2025

    News Taiwan Showcases Evidence-Based TCM at CPHI Frankfurt 2025

    Taiwan's healthcare system, ranked No. 1 worldwide in CEOWORLD Magazine's 2024 Health Care Index, is built on the integration of modern medicine with proven Traditional Chinese Medicine (TCM). At CPHI Frankfurt 2025, organized by Taiwan Institute of Economic Research, the Taiwan Traditional Chinese Medicine Pavilion (stand 12.1 C112) will highlight how Taiwan combines scientific validation with centuries of herbal wisdom to create innovative solutions for global health.
    22 Oct 2025
  • Taiwan Traditional Chinese Medicine Pavilion

    Brochure Taiwan Traditional Chinese Medicine Pavilion

    At CPHI Frankfurt 2025, Taiwan’s National Pavilion will showcase five leading companies — Chuang Song Zong, Li Kang Biotech, Timing Pharmaceutical, Taiwan Three Mast, and Grape King Bio — exemplifying how scientific validation drives commercial innovation in Traditional Chinese Medicine.